Journal of investigative medicine : the official publication of the American Federation for Clinical Research
-
Randomized Controlled Trial
Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.
The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. ⋯ These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.